Global Recombinant Human Somatropin for Injection Supply, Demand and Key Producers, 2023-2029

Global Recombinant Human Somatropin for Injection Supply, Demand and Key Producers, 2023-2029

The global Recombinant Human Somatropin for Injection market size is expected to reach $ 3151.1 million by 2029, rising at a market growth of 3.4% CAGR during the forecast period (2023-2029).

Recombinant Human Somatropin for Injection is a widely used biopharmaceutical in the medical field, primarily employed in the treatment of growth hormone deficiency, short stature, muscle wasting, and related conditions. The market size is substantial, driven by ongoing concerns related to endocrine and growth issues in both children and adults. Sales of the product have steadily increased over the years and are expected to continue to show potential in the future, particularly with the introduction of new therapeutic applications and improved delivery methods, such as enhanced injection devices. Furthermore, as medical science and technology continue to advance, recombinant human somatropin may find applications in a broader spectrum of health fields, creating more opportunities for its future development.

Recombinant Human Somatropin, commonly known as somatropin or human growth hormone (hGH), is a synthetic form of the growth hormone produced naturally in the human body. Somatropin is created using recombinant DNA technology, and it is structurally identical to the growth hormone secreted by the pituitary gland. It is used for various medical and non-medical purposes.

This report studies the global Recombinant Human Somatropin for Injection production, demand, key manufacturers, and key regions.

This report is a detailed and comprehensive analysis of the world market for Recombinant Human Somatropin for Injection, and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Recombinant Human Somatropin for Injection that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global Recombinant Human Somatropin for Injection total production and demand, 2018-2029, (K Units)

Global Recombinant Human Somatropin for Injection total production value, 2018-2029, (USD Million)

Global Recombinant Human Somatropin for Injection production by region & country, production, value, CAGR, 2018-2029, (USD Million) & (K Units)

Global Recombinant Human Somatropin for Injection consumption by region & country, CAGR, 2018-2029 & (K Units)

U.S. VS China: Recombinant Human Somatropin for Injection domestic production, consumption, key domestic manufacturers and share

Global Recombinant Human Somatropin for Injection production by manufacturer, production, price, value and market share 2018-2023, (USD Million) & (K Units)

Global Recombinant Human Somatropin for Injection production by Type, production, value, CAGR, 2018-2029, (USD Million) & (K Units)

Global Recombinant Human Somatropin for Injection production by Application production, value, CAGR, 2018-2029, (USD Million) & (K Units).

This reports profiles key players in the global Recombinant Human Somatropin for Injection market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novo Nordisk, LG Chem, Pfizer, Eli lilly, Merck, Roche, Changchun GeneScience Pharmaceutical, Anhui Anke Biotechnology and Shanghai United Cell Biotechnology, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Recombinant Human Somatropin for Injection market.

Detailed Segmentation:

Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global Recombinant Human Somatropin for Injection Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World

Global Recombinant Human Somatropin for Injection Market, Segmentation by Type
Powder Injection
Aqueous Injection

Global Recombinant Human Somatropin for Injection Market, Segmentation by Application
Hospital
Clinic
Others

Companies Profiled:
Novo Nordisk
LG Chem
Pfizer
Eli lilly
Merck
Roche
Changchun GeneScience Pharmaceutical
Anhui Anke Biotechnology
Shanghai United Cell Biotechnology
Zhongshan Sinobioway Hygene Biomedicine

Key Questions Answered

1. How big is the global Recombinant Human Somatropin for Injection market?

2. What is the demand of the global Recombinant Human Somatropin for Injection market?

3. What is the year over year growth of the global Recombinant Human Somatropin for Injection market?

4. What is the production and production value of the global Recombinant Human Somatropin for Injection market?

5. Who are the key producers in the global Recombinant Human Somatropin for Injection market?